<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The incidence of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> is markedly increased in patients with <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, and the presence of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> is associated with <z:mp ids='MP_0008770'>reduced survival rates</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: We investigated whether the results of screening for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> in patients with <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> using chromoendoscopy would change the treatment of such patients </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS: 87 patients with <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> and known alcohol or <z:chebi fb="164" ids="18723">nicotine</z:chebi> abuse were screened for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: The patients underwent esophagogastroduodenoscopy and staining of the esophagus with 2% Lugol's solution </plain></SENT>
<SENT sid="4" pm="."><plain>Biopsies were taken from unstained areas for histopathological assessment </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">Esophageal cancer</z:e> was newly diagnosed in 10 patients (11.5%), including 2 with <z:mp ids='MP_0002038'>carcinoma</z:mp> in situ </plain></SENT>
<SENT sid="6" pm="."><plain>There were dysplastic changes in 6 patients (7%) and an unknown <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> in 4 patients (5%) </plain></SENT>
<SENT sid="7" pm="."><plain>In 36 patients (41%) unstained areas were associated with <z:hpo ids='HP_0100633'>esophagitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>While unstained areas could not be detected in 17 patients, the histology was <z:mpath ids='MPATH_458'>normal</z:mpath> in 14 patients with unstained areas </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> the patients with newly detected invasive <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, the treatment had to be changed from a curative neoadjuvant approach to palliative treatment </plain></SENT>
<SENT sid="10" pm="."><plain>In 2 patients with <z:mp ids='MP_0002038'>carcinoma</z:mp> in situ mucosectomy was performed </plain></SENT>
<SENT sid="11" pm="."><plain>In the cases with dysplastic areas and newly detected <z:e sem="disease" ids="C1258085" disease_type="Disease or Syndrome" abbrv="">Barrett epithelium</z:e> a careful follow-up regime was arranged </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The staging of patients with <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, and the risk factors for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> should include chromoendoscopy of the esophagus as a standard procedure </plain></SENT>
<SENT sid="13" pm="."><plain>Extended staging provides critical additional information, which helps to more safely distinguish future candidates for curative and palliative treatment </plain></SENT>
</text></document>